Immunotherapy for esophageal carcinoma

Recent progress in gene technology has clarified the existence of some cancer-rejection genes and peptides such as MAGE, MART, etc. Many clinical trials with cancer vaccines have been performed. Since the clinical efficacy of HLA class I-restricted peptide vaccines is still poor, many researchers ar...

Full description

Saved in:
Bibliographic Details
Published inNihon Geka Gakkai zasshi Vol. 103; no. 4; p. 376
Main Author Yamana, Hideaki
Format Journal Article
LanguageJapanese
Published Japan 01.04.2002
Subjects
Aged
Aged, 80 and over
Antigens, Neoplasm
Cancer Vaccines - therapeutic use
Esophageal Neoplasms - therapy
Female
Granulocytes
Humans
Immunotherapy
Immunotherapy, Adoptive
Isoantigens - therapeutic use
Male
Middle Aged
Neoplasm Proteins - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Recent progress in gene technology has clarified the existence of some cancer-rejection genes and peptides such as MAGE, MART, etc. Many clinical trials with cancer vaccines have been performed. Since the clinical efficacy of HLA class I-restricted peptide vaccines is still poor, many researchers are mainly administering dendritic cell therapies. However, there have been few clinicals trials of cancer-specific immunotherapy for esophageal carcinomas. We have performed cancer vaccine therapy with SART-1 peptide and locoregional adoptive immunotherapy with activated autologous lymphocytes for patients with advanced esophageal carcinoma in a phase I and a phase I/II trial, respectively. The clinical responses were poor in the vaccine trial because of the rapid growth of esophageal cancers and the requirement for more than 2 months to activate and increase killer T cells after in vivo vaccination, while locoregional adoptive immunotherapy was effective for the treatment of esophageal cancers even in advanced stages with organ metastases. Based on these results, we think that a combination immunotherapy with adoptive immunotherapy and vaccine therapy is needed for the treatment of advanced esophageal carcinomas.
ISSN:0301-4894